COMPANY

Laurent Pharmaceuticals is a clinical stage biopharmaceutical company focusing on life-threatening inflammatory and fibrotic diseases that are inadequately addressed by current anti-inflammatory therapies.

 

Laurent Pharmaceuticals is a clinical stage biopharmaceutical company focusing on life-threatening inflammatory diseases that are inadequately addressed by current anti-inflammatory therapies.

The company’s lead drug candidate, LAU-7b, is a unique, patent-protected oral formulation of fenretinide, ideally applicable to a once-a-day low dose treatment regimen. LAU-7b has the potential to trigger the resolution phase of inflammation and is currently in a Phase 2 study involving adult patients with Cystic Fibrosis. Fenretinide also showed potent antiviral effects in vitro against the SARS-CoV-2 virus, and the company is currently conducting a Phase 2 clinical trial with LAU-7b in hospitalized COVID-19 patients.